Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists

Askling, Johan; Fored, C. Michael; Baecklund, Eva; Brandt, Lena; Backlin, Carin; Ekbom, Anders; Sundström, Christer; Bertilsson, L; Cöster, L; Geborek, Pierre; Jacobsson, L. T. H.; Lindblad, Staffan; Lysholm, J; Rantapää‐Dahlqvist, Solbritt; Saxne, Tore; Klareskog, Lars; Feltelius, Nils

doi:10.1136/ard.2004.033241

Cited by 374 publications

(267 citation statements)

References 28 publications

Supporting

Mentioning

225

Contrasting

Unclassified

Order By: Relevance

“…Supporting this observation, Askling et al (2005b) found two-fold increased risks of AML and CML in a large Swedish cohort study of patients hospitalised for rheumatoid arthritis. Although MDS is a chronic condition, we saw an association with rheumatoid arthritis even after excluding the 5-year period before diagnosis/selection, arguing against reverse causality (i.e., that undiagnosed MDS caused rheumatoid arthritis).…”

Section: Discussionsupporting

confidence: 52%

“…Although reported more commonly for lymphoproliferative neoplasms (Zintzaras et al, 2005;Ekstrom Smedby et al, 2008), increased risks in persons with autoimmune conditions have also been noted for myeloid malignancies, including AML and CML (Zheng et al, 1993;Askling et al, 2005b). Autoimmune conditions, which occur commonly in patients with MDS (Voulgarelis et al, 2004), have also been reported to precede MDS (Dalamaga et al, 2002).…”

mentioning

confidence: 99%

See 1 more Smart Citation

Risks of myeloid malignancies in patients with autoimmune conditions

et al. 2009

View full text Add to dashboard Cite

Autoimmune conditions are associated with an elevated risk of lymphoproliferative malignancies, but few studies have investigated the risk of myeloid malignancies. From the US Surveillance Epidemiology and End Results (SEER)-Medicare database, 13 486 myeloid malignancy patients (aged 67 þ years) and 160 086 population-based controls were selected. Logistic regression models adjusted for gender, age, race, calendar year and number of physician claims were used to estimate odds ratios (ORs) for myeloid malignancies in relation to autoimmune conditions. Multiple comparisons were controlled for using the Bonferroni correction (Po0.0005).

show abstract

Section: Discussionsupporting

confidence: 52%

mentioning

confidence: 99%

Risks of myeloid malignancies in patients with autoimmune conditions

et al. 2009

View full text Add to dashboard Cite

show abstract

“…Standardized incidence ratio (SIR) values vary from 2.6 to 11.5 in anti-TNF-treated groups compared to the general population. One study that compared the rate of lymphoma in TNF-treated RA patients to a control RA group found no increased risk [100]. A recent cohort study of 1152 biologic users and 7306 MTX users from 2 US states and 1 Canadian province [99] demonstrated a propensity score-adjusted pooled hazard ratio was 1.37 (95% CI 0.71-2.65) for hematologic malignancies and 0.91 (95% CI 0.65-1.26) for solid tumors, which does not support the likelihood of increased risk of malignancies by the use of biologic agents compared to MTX.…”

Section: Non-infectious Adverse Consequences Of Tnfα Antagonists Malimentioning

confidence: 99%

TNFα blockade in human diseases: An overview of efficacy and safety

Lin

Ziring

Desai

et al. 2008

Clinical Immunology

233

188

View full text Add to dashboard Cite

show abstract

“…Contraindications for using all classes of biologics are active infections, congestive heart failure, pregnancy and breast feeding [10][11][12] . Malignancies appear to be increased in RA, however there appears to be no additional increased risk in RA patients treated with biologics 13,14 . Infusion and injection site reactions are the commonest side effects.…”

Section: Biologic Use In Autoimmune Joint Diseasesmentioning

confidence: 99%